Ocular angiostatic agents

Clark, Abbot F.; Bingaman, David P.; Kapin, Michael A.

doi:10.1517/13543776.10.4.427

Cited by 8 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If ocular research periodicals specifically address patenting at all, it is to discuss controversial uses of the system,1,2 or to investigate the interaction of sponsorship with research 3,4. Systematic reviews of ocular patenting activity are usually published in journals that are focused either on patenting5–9 or on general drug discovery and development 10,11…”

Section: Introductionmentioning

confidence: 99%

International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics

Mucke¹

2008

OPTH

View full text Add to dashboard Cite

While investigative ophthalmologists access peer-reviewed journals as part of their daily routine, and while they regularly visit scientific congresses, they rarely peruse patent documents as an information source. Among the reasons for this negligence are the incompatibility of patent search algorithms with those known from journal databases, a legalistic and frequently redundant language, and misconceptions about the nature of the patenting system. Here we present key data and analyses from the ophthalmology module of a patent database system that we are developing to address some of these problems. We show that international patent applications consistently reflect developer interest in the ocular drug and diagnostics field; that they are technically focused lead indicators of developments that frequently feature in peer-reviewed patenting only much later; and that patenting targets are well aligned with the unmet therapeutic needs of populations in industrialized countries. Most applications (74%–78% in years since 2006) are supported with experimental data, and most (on average, 80%–90%) faced at least one objection to patentability during their initial stage of examination. In contrast to the peer-reviewed scenery that is highly diverse, the corresponding patenting arena shows a pronounced focus on the United States.

show abstract

Section: Introductionmentioning

confidence: 99%

International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics

Mucke¹

2008

OPTH

View full text Add to dashboard Cite

show abstract

“…The application of novel angiostatic agents, particularly proteins or protein-like drugs including anti-vascular endothelial growth factor (VEGF) (17) 7 , matrix metalloproteinase (MMP) inhibitors (18,19), integrin agonists (20), pigment epithelium-derived factor (PEDF) (21,22), and inhibitors of insulin-like growth factor-1 and growth hormone (23), will require more sophisticated methods of delivery to ensure activity and efficacy of the drug over a prolonged period of time and to minimize drug-induced complications. Novel delivery systems are also needed for therapeutics with a high level of systemic toxicity, such as steroids (24)(25)(26) 6 .…”

Section: Sheardown and Saltzmanmentioning

confidence: 99%